{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Barinthus Biotherapeutics plc"},"Symbol":{"label":"Symbol","value":"BRNS"},"Address":{"label":"Address","value":"OX4 4GE, United Kingdom"},"Phone":{"label":"Phone","value":"+44 1865818808"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca."},"CompanyUrl":{"label":"Company Url","value":"https://www.barinthusbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Geoffrey Lynn","title":"Chief Scientific Officer"},{"name":"Leon Hooftman","title":"Chief Medical Officer"},{"name":"William Enright","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}